Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $10.00 target price on the stock. D. Boral Capital’s price objective would suggest a potential upside of 280.23% from the company’s current price.

ANIX has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, March 25th. Maxim Group initiated coverage on Anixa Biosciences in a report on Friday, March 21st. They set a “buy” rating and a $10.00 price objective on the stock.

Anixa Biosciences Stock Down 2.2 %

Shares of ANIX traded down $0.06 during midday trading on Thursday, hitting $2.63. The company’s stock had a trading volume of 18,635 shares, compared to its average volume of 96,572. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The company’s fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $2.96. The stock has a market capitalization of $84.68 million, a price-to-earnings ratio of -6.74 and a beta of 0.52.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, research analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were bought at an average cost of $2.57 per share, with a total value of $25,700.00. Following the purchase, the director now directly owns 922,334 shares of the company’s stock, valued at $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Amit Kumar acquired 43,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 75,289 shares of company stock valued at $177,021. 25.30% of the stock is currently owned by company insiders.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIX. Focus Partners Wealth bought a new stake in Anixa Biosciences in the 4th quarter valued at about $162,000. Jane Street Group LLC purchased a new position in shares of Anixa Biosciences in the 4th quarter worth approximately $67,000. Prosperity Wealth Management Inc. purchased a new position in shares of Anixa Biosciences in the 4th quarter worth approximately $54,000. Westside Investment Management Inc. boosted its stake in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in shares of Anixa Biosciences by 37.2% in the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after buying an additional 11,633 shares during the last quarter. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.